← Eichor
Study identifier: NCT07097142 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Condition: Muscle Invasive Bladder Urothelial Carcinoma · Stage II Bladder Cancer AJCC v8 · Stage IIIA Bladder Cancer AJCC v8  ·  Sponsor: NRG Oncology

PhasePhase 3
Planned participants486
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine or mitomycin and 5-fluorouracil for the treatment of patients with muscle invasive bladder cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a short period of time. Ultra-hypofractionated radiation therapy delivers radiation over an even shorter period of time than hypofractionated radiation therapy. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Chemotherapy drugs, such as mitomycin-C and 5-fluorouracil (5-FU), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ultra-hypofractionated radiation may be equally effective as hypofractionated therapy for patients with muscle invasive bladder cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (211)

Mercy Hospital Fort SmithFort Smith, Arkansas, United StatesRecruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine, California, United StatesRecruiting
UC San Diego Moores Cancer CenterLa Jolla, California, United StatesRecruiting
UC Irvine Health/Chao Family Comprehensive Cancer CenterOrange, California, United StatesRecruiting
University of California Davis Comprehensive Cancer CenterSacramento, California, United StatesRecruiting
UCHealth University of Colorado HospitalAurora, Colorado, United StatesRecruiting
UCHealth - Cherry CreekDenver, Colorado, United StatesRecruiting
UCHealth Highlands Ranch HospitalHighlands Ranch, Colorado, United StatesRecruiting
UCHealth Lone Tree Health CenterLone Tree, Colorado, United StatesRecruiting
Beebe Medical CenterLewes, Delaware, United StatesRecruiting
Beebe South Coastal Health CampusMillville, Delaware, United StatesRecruiting
Helen F Graham Cancer CenterNewark, Delaware, United StatesRecruiting

+ 199 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07097142